Trump demands pharma CEOs lower drug prices within 60 days
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Leerink: 'We continue to recommend REGN shares'
August 4, 2025 10:20 AM EDTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $645.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Bottom Line: We continue to recommend REGN shares based upon improving growth prospects and attractive valuation. We project 5-yr (2025-2030) CAGR rev +7% and EPS +10%. Mgmt emphasized Lynozyfics... More
